Lithium rebound could come sooner than you think
Battery energy storage systems could be the wildcard for lithium demand, as one analyst predicts an earlier than expected price bounce.
News
Asia looms as new gold haven
These forward-looking ASX-listed resource juniors are proving that their Asian gold resources that have the hallmarks of significant plays.
Predator and Prey: Asra Minerals
Predator and Prey analyses emerging explorers and why they might attract acquisition interest. This time we’re looking at Asra Minerals.
ASX biotechs take on traumatic brain injury
Advocates of TBI awareness are pushing for better care while ASX companies drop devices and drugs that are stepping up the fight.
ASX up 1.2pc as tech shines, jobs dip
ASX rises +1pc, Nanosonics jumps after FDA approval, and Aussie job numbers dip, sparking rate cut hopes.
Silver bulls lead ASX explorers higher
Gold has been grabbing the headlines as it ventures above the US$3000/oz mark, but the quiet achievers have been silver stocks.
Nanosonics shares soar on FDA approval
The US Food and Drug Administration has approved Nanosonics’ next-generation medical probe sterilising device, dubbed Coris.
ASX rebounds, Nanosonics gets FDA nod
The ASX has bounced back after Wall Street’s surge. Meanwhile Nanosonics has soared on FDA approval, and Bitcoin is back above $86k while gold grabbed another personal best.
Time for a bit of ‘portfolio medicine’
In a softening market, Precision Funds Management’s Dermot Woods and Andy Clayton are eyeing off opportunities to upgrade their portfolio.
Is AI trade dead or just in a rough patch?
AI stocks are tumbling as Trump tariffs bite. Here’s what Stake’s Samy Sriram says investors should do.
How to pick a copper winner
Copper prices have surged beyond US$5 a pound. But how do you know a copper stock could be a winner?
Korean battery development powering up
Global battery deployment reached all time highs in 2024, and South Korean player EcoPro is partnering with ASX miners to maintain the pace.
Almonty strong on tungsten deal
Almonty Industries has continued its strong recent run, securing a partnership deal for tungsten concentrate with American Defense International.
ASX snaps win streak, eyes now on Fed’s move
ASX gets smacked by Wall Street sell-off, MinRes tumbles after haul road drama, and all eyes are now on the Fed’s next move.
ASX rocky, MinRes tumbles 7pc after mis
The ASX has taken a hit as Wall Street’s nerves spread. Meanwhile the Fed is likely to keep things steady, and MinRes and Wisetech face a rough day.
Break it Down: EmVision Medical Devices
EMVision’s completed further testing of its proof-of-concept First Responder device for traumatic brain and stroke injuries.
Emvision’s stroke detector passes first high-flying test
Royal Flying Doctor Service paramedics have successfully tested Emvision’s portable stroke detector, First Responder.
FDA approval remains Holy Grail for Aussie biotechs
Despite concerns about the Trump government’s shake-up of the agency, the US Food and Drug Administration remains the first port of call for most ASX biotechs.
ASX pharmas playing the long game
ASX pharmaceutical companies are retaining their assets longer and advancing them to commercialisation in a bid to maximise value.
OMA rated a speculative buy by Morgans
Omega Oil and Gas has been judged a speculative buy with a 64c price target by Morgans as it flow tests its Canyon-1H well.
Spectacular visible gold lifts Trek
Trek Metals is on the hunt for a deposit of major scale and has picked up the pace of exploration at Christmas Creek in the Kimberley, not far south of Halls Creek.
Break it Down: Orthocell
Orthocell’s Striate+ lands in its next major market, Singapore, priming the company for further launches in the ASEAN region.
ASX dips as tensions rise; gold hits record
The ASX dipped on Tuesday afternoon after Israel’s airstrikes rattled nerves, while gold hit a new high and New Hope coal soared.
ASX climbs again, UBS targets US$3200 for gold
ASX rises for a third day, Tesla drops 5%, copper hits 5-month high and UBS sees gold reaching US$3200.
This rare blood disease tackler has a shot
The myelofibrosis drug landscape has become more crowded since Syntara decided to focus on the disease in 2020, but the company is giving investors its best shot.
Original URL: https://www.theaustralian.com.au/business/stockhead/news